- Clinical Stem Cell Services
- GMP iPSC/MSC MCB Manufacturing – Histocell (Europe Partner Overview)
Histocell – our GMP iPSC and MSC Manufacturing Partner in Europe

Located in Bilbao, Spain, Histocell is a CDMO and a clinical-stage biopharmaceutical company that specializes in developing cell therapy products for regenerative medicine.
Histocell's highly reliable and qualified scientific team has more than 20 years of experience. They will take care of your iPSC or MSC cell therapy needs with a flexible and scalable manufacturing process.
In the REPROCELL-Histocell GMP stem cell services partnership:
- Histocell manufactures investigational medicinal products for human use for European, US, and Japanese customers.
- Histocell also provides all regulatory safety and quality controls specified by regulatory authorities and all additional required documentary support for the cells.
Authorized GMP facility for Manufacturing Clinical Grade Products
Histocell's newly built 800 m2 GMP facility is already authorized and registered by the European Union Manufacturer Authorization (EMA) for the manufacturing of clinical grade cells in compliance with the GMP guidelines of EMA Regulation (EU) 2017/1569.
Advanced Therapy Medicinal Products (ATMPs) Manufacturing
Since 2011, Histocell has been an authorized provider of GMP ATMPs manufacturing services to clients around the world.
Around 300 patients have already been treated with ATMPs manufactured by Histocell, and more than 350 batches have been manufactured under GMP.
Advanced Therapy Cell Production Facilities
Histocell's new Advanced Therapies GMP cell production unit has 800 m2 of capacity.
- GMP manufacturing suites and associated infrastructure
- Fully equipped to manufacture both autologous and allogeneic therapies
- Manufacturing and storage for cell therapy stocks (MCB, WCB)
- Production and characterization of cell-derived biologics such as secretomes and exosomes
- Manufacturing capability: approx. 1200 batches/year
- Designed to support both pre-clinical and clinical phases
- Histocell is also gearing up to support commercial manufacturing
Services We Offer In Partnership With Histocell
Working together, REPROCELL and Histocell are well placed to support your GMP stem cell manufacturing project.
Ask our experts about our GMP services
Discover More
Resources
- FAQ: Clinical iPSCs
- FAQ: Clinical MSCs
- FAQ: iPSC-Derived Exosomes
- Making iPSC-Derived Therapeutics a Clinical Reality – our external article in the European Biopharmaceutical Review.
On the REPROCELL blog
Latest in Stem Cells
AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
REPROCELL's StemEdit platform enables the creation of hypoimmune iPSCs for scalable off-the-shelf cell therapies, reducing immune rejection and enhancing patient access.
04 June 2026
What Are Off-Target Effects in Cellular Gene Editing? Risks, Detection, and Solutions
Explore off-target effects in gene editing, from CRISPR risks and AI-driven detection to genomic safety in iPSC therapies.
20 May 2026
5 Hard Truths About Bringing Stem Cell Therapies to the Clinic
Discover the essential truths behind developing clinical-grade stem cell therapies and learn how to navigate the complexities of GMP manufacturing successfully.
30 March 2026




